Literature DB >> 16219310

Identification and analysis of Hic-5/ARA55 isoforms: Implications for integrin signaling and steroid hormone action.

Zhengliang Gao1, Lawrence M Schwartz.   

Abstract

Hic-5/ARA55 is a LIM-only member of the paxillin superfamily. Conflicting reports have suggested that Hic-5/ARA55 can both repress and enhance a number of biological processes, including myogenesis and tumorigenesis. With two Hic-5 isoforms documented, we hypothesized that multiple Hic-5 isoforms may exist that have both overlapping and isoform-specific functions. To test this hypothesis, we performed an extensive analysis of Hic-5 transcripts in both cell lines and mouse tissues and found 12 distinct isoforms that fall into two sub-families. These isoforms are derived from both alternative splicing and alternative transcriptional start sites (TSS). Hic-5 expression is regulated in a temporally and spatially controlled manner in vivo. The identification of numerous Hic-5 isoforms suggests that Hic-5 subsumes a number of distinct roles in cells and may explain the range of biological responses attributed to Hic-5.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219310     DOI: 10.1016/j.febslet.2005.08.086

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Paxillin and hydrogen peroxide-inducible clone 5 expression and distribution in control and Alzheimer disease hippocampi.

Authors:  John Caltagarone; Ronald L Hamilton; Geoffrey Murdoch; Zheng Jing; Donald B DeFranco; Robert Bowser
Journal:  J Neuropathol Exp Neurol       Date:  2010-04       Impact factor: 3.685

2.  Hic-5 Regulates Actin Cytoskeletal Reorganization and Expression of Fibrogenic Markers and Myocilin in Trabecular Meshwork Cells.

Authors:  Padmanabhan Paranji Pattabiraman; Ponugoti Vasantha Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

3.  Hic-5 controls BMP4 responses in prostate cancer cells through interacting with Smads 1, 5 and 8.

Authors:  D T N Shola; H Wang; R Wahdan-Alaswad; D Danielpour
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.